In the treatment of adult AML patients, IA regimen is associated with a high CR rate and ORR rate and does not increase treatment-related toxicity. IA regimen prolongs OS and PFS in AML patients and reduces the likelihood of leukemia cells' subsequent infiltration into the central nervous system. There is a high correlation between the level of MRD after treatment and the patient's bone marrow recurrence. To obtain superior treatment effects for patients undergoing allo-HSCT, the MRD should be reduced to less than 0.001 before pretreatment. A negative MRD before allo-HSCT can prolong OS in patients with AML. We examined the clinical characteristics and outcomes of AML patients in China, finding novel information on prognostic factors and primary treatment of AML that may be applicable in routine clinical practice.
Keyphrases
- acute myeloid leukemia
- prognostic factors
- end stage renal disease
- bone marrow
- newly diagnosed
- chronic kidney disease
- ejection fraction
- patients undergoing
- clinical practice
- healthcare
- mesenchymal stem cells
- allogeneic hematopoietic stem cell transplantation
- adipose tissue
- metabolic syndrome
- signaling pathway
- acute lymphoblastic leukemia
- combination therapy
- oxide nanoparticles